ROSEN, LEADING TRIAL ATTORNEYS, Encourages Alto Neuroscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ANRO

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Alto Neuroscience, Inc. about a class action lawsuit related to misleading statements made during the company's IPO and subsequent period [1][5]. Group 1: Class Action Details - The class action pertains to investors who purchased Alto securities during the IPO on February 2, 2024, and up until October 22, 2024 [1]. - A lead plaintiff deadline has been set for September 19, 2025, for those wishing to represent the class [1][3]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Allegations Against Alto Neuroscience - The lawsuit claims that Alto made materially false and misleading statements regarding its business and the effectiveness of its product ALTO-100 in treating major depressive disorder [5]. - Specific allegations include that ALTO-100 was less effective than represented, leading to overstated clinical, regulatory, and commercial prospects [5]. - The misleading statements resulted in damages to investors when the true information became public [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in handling such cases [4].